دورية أكاديمية
Medulloblastoma and the DNA Damage Response.
| العنوان: | Medulloblastoma and the DNA Damage Response. |
|---|---|
| المؤلفون: | McSwain LF; Department of Pediatrics, Emory University, Atlanta, GA, United States., Parwani KK; Winship Cancer Institute, Emory University, Atlanta, GA, United States.; Department of Radiation Oncology, Emory University, Atlanta, GA, United States., Shahab SW; Winship Cancer Institute, Emory University, Atlanta, GA, United States., Hambardzumyan D; Departments of Neurosurgery and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., MacDonald TJ; Department of Pediatrics, Emory University, Atlanta, GA, United States.; Winship Cancer Institute, Emory University, Atlanta, GA, United States., Spangle JM; Winship Cancer Institute, Emory University, Atlanta, GA, United States.; Department of Radiation Oncology, Emory University, Atlanta, GA, United States., Kenney AM; Department of Pediatrics, Emory University, Atlanta, GA, United States. |
| المصدر: | Frontiers in oncology [Front Oncol] 2022 Jun 07; Vol. 12, pp. 903830. Date of Electronic Publication: 2022 Jun 07 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Medulloblastoma (MB) is the most common malignant brain tumor in children with standard of care consisting of surgery, radiation, and chemotherapy. Recent molecular profiling led to the identification of four molecularly distinct MB subgroups - Wingless (WNT), Sonic Hedgehog (SHH), Group 3, and Group 4. Despite genomic MB characterization and subsequent tumor stratification, clinical treatment paradigms are still largely driven by histology, degree of surgical resection, and presence or absence of metastasis rather than molecular profile. Patients usually undergo resection of their tumor followed by craniospinal radiation (CSI) and a 6 month to one-year multi-agent chemotherapeutic regimen. While there is clearly a need for development of targeted agents specific to the molecular alterations of each patient, targeting proteins responsible for DNA damage repair could have a broader impact regardless of molecular subgrouping. DNA damage response (DDR) protein inhibitors have recently emerged as targeted agents with potent activity as monotherapy or in combination in different cancers. Here we discuss the molecular underpinnings of genomic instability in MB and potential avenues for exploitation through DNA damage response inhibition. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 McSwain, Parwani, Shahab, Hambardzumyan, MacDonald, Spangle and Kenney.) |
| References: | J Neurooncol. 2020 May;147(3):531-545. (PMID: 32180106) Thromb Haemost. 2014 Mar 3;111(3):508-17. (PMID: 24352480) Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7. (PMID: 17892918) Br J Cancer. 2010 Nov 9;103(10):1588-96. (PMID: 20978505) DNA Repair (Amst). 2021 May;101:103074. (PMID: 33640757) DNA Repair (Amst). 2013 Aug;12(8):620-36. (PMID: 23684800) Diagn Pathol. 2014 Jul 01;9:132. (PMID: 24986561) Neurosurgery. 2012 Apr;70(4):1003-10; discussion 1010. (PMID: 22037313) J Oncol. 2012;2012:951724. (PMID: 22481935) Cancer Cell. 2017 Jun 12;31(6):737-754.e6. (PMID: 28609654) J Exp Clin Cancer Res. 2019 Jul 5;38(1):287. (PMID: 31277672) Oncogene. 1997 Oct;15(18):2145-50. (PMID: 9393972) Sci Rep. 2016 Jun 03;6:27012. (PMID: 27255663) Oncogene. 2020 Jan;39(5):1041-1048. (PMID: 31582835) Cancer Res. 2021 Apr 1;81(7):1627-1632. (PMID: 33509943) Acta Neuropathol. 2016 Jun;131(6):821-31. (PMID: 27040285) Antioxid Redox Signal. 2014 Jul 10;21(2):251-9. (PMID: 24180216) J Neurooncol. 1996 Jul;29(1):1-7. (PMID: 8817411) Oncogene. 2019 Oct;38(42):6867-6879. (PMID: 31406250) Invest New Drugs. 2016 Jun;34(3):355-63. (PMID: 26996385) J Biol Chem. 2010 Nov 26;285(48):37218-26. (PMID: 20876583) Clin Cancer Res. 2016 Jun 15;22(12):2840-7. (PMID: 27306791) Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. (PMID: 31099635) Oncotarget. 2017 Jul 18;8(29):46915-46927. (PMID: 28159923) J Pak Med Assoc. 2018 Jul;68(7):1137-1139. (PMID: 30317322) Neurol Clin. 1985 Nov;3(4):843-53. (PMID: 3908899) Cancer Res. 2010 Jan 1;70(1):266-76. (PMID: 20028853) Mol Cell Biol. 2016 May 02;36(10):1426-37. (PMID: 26976642) Mol Cancer Ther. 2014 Feb;13(2):433-43. (PMID: 24356813) Oncogene. 2014 Jul 24;33(30):3959-69. (PMID: 24096481) Clin Cancer Res. 2021 Mar 15;27(6):1585-1594. (PMID: 33082213) Front Pharmacol. 2021 Apr 29;12:662232. (PMID: 33995085) Nat Rev Dis Primers. 2019 Feb 14;5(1):11. (PMID: 30765705) Cancer Res. 2006 May 15;66(10):5190-200. (PMID: 16707443) Cancer Res. 2008 Nov 15;68(22):9404-12. (PMID: 19010915) J Mol Med (Berl). 2017 Jun;95(6):589-599. (PMID: 28439615) Neuro Oncol. 2014 May;16(5):748-53. (PMID: 24482446) Oncotarget. 2018 Mar 30;9(24):16619-16633. (PMID: 29682173) Antioxid Redox Signal. 2009 Mar;11(3):601-20. (PMID: 18976116) Neuro Oncol. 2014 Oct;16(10):1313-23. (PMID: 24811392) J Clin Oncol. 2013 Aug 10;31(23):2927-35. (PMID: 23835706) Oncotarget. 2016 Aug 16;7(33):53881-53894. (PMID: 27449089) Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. (PMID: 31409614) Mol Cell Biol. 2013 Jan;33(2):387-95. (PMID: 23149936) Clin Cancer Res. 2001 Nov;7(11):3510-8. (PMID: 11705870) Oncogene. 2016 Oct 20;35(42):5552-5564. (PMID: 27086929) Curr Top Dev Biol. 2011;94:235-82. (PMID: 21295689) Diagnostics (Basel). 2021 Dec 28;12(1):. (PMID: 35054230) Cell Death Dis. 2021 May 18;12(6):503. (PMID: 34006852) Semin Cancer Biol. 2018 Feb;48:1-17. (PMID: 28591657) Cancer Med. 2017 Nov;6(11):2606-2624. (PMID: 28980418) Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88. (PMID: 29117289) Annu Rev Biochem. 2016 Jun 2;85:375-404. (PMID: 27145840) Cell Death Differ. 1995 Oct;2(4):267-75. (PMID: 17180032) Annu Rev Biochem. 1994;63:915-48. (PMID: 7979257) Pharmacol Res. 2018 Nov;137:104-113. (PMID: 30278221) Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6048-53. (PMID: 9177166) Cancer Cell. 2014 Mar 17;25(3):393-405. (PMID: 24651015) J Nucleic Acids. 2010 Nov 21;2010:543531. (PMID: 21113301) Nat Rev Cancer. 2004 Apr;4(4):296-307. (PMID: 15057289) J Neurooncol. 2008 Feb;86(3):245-56. (PMID: 17932621) Nat Genet. 2021 Apr;53(4):529-538. (PMID: 33753930) Cancer Res. 1999 Aug 15;59(16):3968-71. (PMID: 10463593) Carcinogenesis. 2008 Oct;29(10):1911-9. (PMID: 18660545) Cancer Res. 1991 Sep 1;51(17):4721-3. (PMID: 1873817) Nature. 2017 Jul 19;547(7663):311-317. (PMID: 28726821) Annu Rev Genet. 1986;20:201-30. (PMID: 3545059) Mol Biol Rep. 2020 Dec;47(12):9931-9937. (PMID: 33159234) Genes Dev. 2008 Feb 15;22(4):436-48. (PMID: 18281460) Sci Signal. 2018 Sep 11;11(547):. (PMID: 30206138) J Cell Biol. 2008 Nov 3;183(3):385-91. (PMID: 18955550) Radiat Oncol J. 2016 Dec;34(4):239-249. (PMID: 28030900) Neuro Oncol. 2007 Oct;9(4):384-92. (PMID: 17704359) Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1880-5. (PMID: 19164512) Acta Neuropathol. 2012 Apr;123(4):473-84. (PMID: 22358457) Leukemia. 2020 Nov;34(11):2858-2874. (PMID: 32651541) Dev Biol. 2015 Jan 15;397(2):191-202. (PMID: 25448692) CNS Oncol. 2012 Sep;1(1):85-97. (PMID: 25054302) J Med Chem. 2011 Jan 27;54(2):635-54. (PMID: 21174434) Oncogene. 2005 Apr 18;24(17):2899-908. (PMID: 15838523) Cancer Biol Ther. 2013 May;14(5):379-89. (PMID: 23380594) Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28. (PMID: 24579667) Pediatr Neurosurg. 1996;24(2):74-8. (PMID: 8841077) J Nucleic Acids. 2010 Dec 27;2010:182894. (PMID: 21234397) Neuro Oncol. 2002 Apr;4(2):115-22. (PMID: 11916503) Front Oncol. 2016 Jan 27;6:7. (PMID: 26858935) J Neurooncol. 2010 Apr;97(2):217-24. (PMID: 19779861) Acta Neuropathol. 2014;127(6):931-3. (PMID: 24699697) Acta Neuropathol. 2012 Apr;123(4):465-72. (PMID: 22134537) NPJ Syst Biol Appl. 2017 Mar 6;3:8. (PMID: 28649435) Exp Mol Med. 2014 Jul 18;46:e106. (PMID: 25033834) Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33472956) Clin Cancer Res. 2013 Dec 1;19(23):6484-94. (PMID: 24036851) Clin Cancer Res. 2008 Nov 1;14(21):6761-9. (PMID: 18980969) Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12285-E12294. (PMID: 30538199) Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621. (PMID: 28676700) Cell Death Dis. 2020 Sep 24;11(9):797. (PMID: 32973135) Pediatr Blood Cancer. 2020 Jan;67(1):e28032. (PMID: 31595663) Curr Opin Pediatr. 1994 Dec;6(6):632-5. (PMID: 7849806) Mol Cancer Res. 2019 Jan;17(1):186-198. (PMID: 30224541) PLoS One. 2011 Mar 18;6(3):e17884. (PMID: 21437245) Oncogene. 2006 Feb 23;25(8):1165-73. (PMID: 16407852) Neurosci Lett. 2012 Mar 28;513(1):106-10. (PMID: 22343310) Cancer Lett. 2018 Aug 28;430:34-46. (PMID: 29753759) Oncogene. 2010 Nov 18;29(46):6149-59. (PMID: 20729914) Genes Dev. 2000 Apr 15;14(8):994-1004. (PMID: 10783170) Mol Cell Oncol. 2015 Sep 11;3(2):e1079673. (PMID: 27308604) Cold Spring Harb Perspect Med. 2013 Nov 01;3(11):. (PMID: 24186490) Oncogene. 2006 Sep 7;25(40):5575-80. (PMID: 16636673) Cancer Res. 1994 Nov 1;54(21):5649-51. (PMID: 7923211) Cancer Cell. 2015 Jan 12;27(1):72-84. (PMID: 25533335) Am J Pathol. 2003 Jan;162(1):343-52. (PMID: 12507917) Cell. 2017 Apr 20;169(3):381-405. (PMID: 28431241) Exp Hematol Oncol. 2019 Nov 11;8:29. (PMID: 31737426) Cell Cycle. 2010 Aug 1;9(15):3012-21. (PMID: 20714216) Am J Cancer Res. 2016 Mar 15;6(4):806-18. (PMID: 27186432) Cancer Cell. 2003 May;3(5):421-9. (PMID: 12781359) Cell. 2007 Jun 29;129(7):1261-74. (PMID: 17604717) Expert Rev Neurother. 2012 Jul;12(7):871-84. (PMID: 22853794) Cell Cycle. 2011 Jul 1;10(13):2218-32. (PMID: 21623170) Cell Biosci. 2020 Apr 1;10(1):54. (PMID: 32266056) Cancer Res. 2002 Nov 15;62(22):6395-9. (PMID: 12438222) Neuro Oncol. 2019 Jun 10;21(6):786-799. (PMID: 30852603) Development. 2003 Jan;130(1):15-28. (PMID: 12441288) Genes Dev. 2005 Nov 15;19(22):2656-67. (PMID: 16260494) Oncotarget. 2011 Dec;2(12):984-96. (PMID: 22184287) Cell Div. 2012 Feb 28;7(1):6. (PMID: 22373487) Nat Commun. 2019 Jul 2;10(1):2910. (PMID: 31266951) Annu Rev Med. 2015;66:129-43. (PMID: 25423595) Mol Cancer. 2020 Jun 20;19(1):107. (PMID: 32563252) J Neurosurg Pediatr. 2019 Oct 1;24(4):353-363. (PMID: 31574483) Oncogene. 1999 Jan 28;18(4):1033-40. (PMID: 10023679) Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10017-22. (PMID: 16777961) Anticancer Drugs. 2013 Nov;24(10):1007-19. (PMID: 23962902) Cancer Cell. 2007 Oct;12(4):342-54. (PMID: 17936559) Biochem Biophys Res Commun. 2018 Oct 28;505(2):548-553. (PMID: 30274781) Radiother Oncol. 2018 Mar;126(3):450-464. (PMID: 29054375) Cold Spring Harb Perspect Med. 2016 May 02;6(5):. (PMID: 27048304) Oncogene. 2002 Oct 24;21(49):7580-4. (PMID: 12386820) Development. 2016 Nov 1;143(21):4038-4052. (PMID: 27803059) J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. (PMID: 24650937) Cold Spring Harb Perspect Med. 2014 Apr 01;4(4):a014373. (PMID: 24692190) Nat Rev Cancer. 2020 Feb;20(2):74-88. (PMID: 31686003) Cancer Lett. 2014 Mar 28;344(2):157-65. (PMID: 24262662) Oncogene. 2006 Nov 16;25(54):7159-65. (PMID: 16751807) Neuro Oncol. 2012 Jul;14(7):859-69. (PMID: 22591662) Clin Cancer Res. 2005 Oct 15;11(20):7405-14. (PMID: 16243814) Biomed Pharmacother. 2019 Mar;111:666-675. (PMID: 30611991) Acta radiol. 1953 Apr;39(4):323-36. (PMID: 13057640) Cancer Cell. 2018 Jun 11;33(6):1004-1016.e5. (PMID: 29894688) J Neurooncol. 2001 Mar;52(1):57-62. (PMID: 11451203) J Clin Oncol. 2006 Sep 1;24(25):4202-8. (PMID: 16943538) DNA Repair (Amst). 2004 Jan 5;3(1):1-12. (PMID: 14697754) Clin Cancer Res. 2004 Dec 1;10(23):7875-83. (PMID: 15585620) Sci Rep. 2019 Sep 6;9(1):12822. (PMID: 31492956) Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. (PMID: 31594388) Clin Chim Acta. 2015 Jan 1;438:139-47. (PMID: 25172038) Clin Cancer Res. 2002 Sep;8(9):3008-18. (PMID: 12231548) Mol Oncol. 2015 Jun;9(6):1071-80. (PMID: 25681012) Diagn Mol Pathol. 1993 Mar;2(1):23-8. (PMID: 8287222) |
| معلومات مُعتمدة: | R01 NS110386 United States NS NINDS NIH HHS |
| فهرسة مساهمة: | Keywords: medulloblastoma; p53 status; pediatrics; radiation oncology; therapeutic targeting |
| تواريخ الأحداث: | Date Created: 20220624 Latest Revision: 20221011 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9209741 |
| DOI: | 10.3389/fonc.2022.903830 |
| PMID: | 35747808 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.903830 |